Diabetic Eye Disease

More than 50 million people are suffering from blindness worldwide. In addition, the number of blinded patients is increasing. Cataract, diabetic retinopathy, age-related macular degeneration, and corneal disorders are major causes of blindness. Advanced glycation end products (AGEs) have a central role in the development of the above ocular diseases. Understanding the mechanism of AGE formation will be a clue to the prevention and treatment of major causes of blindness.

[1]  P. Mitchell,et al.  Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. , 1996, Ophthalmology.

[2]  Hiroshi Yamamoto,et al.  Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. , 2007, Investigative ophthalmology & visual science.

[3]  P. Oates,et al.  Aldose reductase, ocular diabetic complications and the development of topical Kinostat® , 2016, Progress in Retinal and Eye Research.

[4]  J. Baynes,et al.  N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. , 1997, The Biochemical journal.

[5]  Jin Hyoung Kim,et al.  RAGE mediated intracellular Aβ uptake contributes to the breakdown of tight junction in retinal pigment epithelium , 2015, Oncotarget.

[6]  A. Saxena,et al.  Advanced glycation end products and diabetic retinopathy , 2012, Journal of ocular biology, diseases, and informatics.

[7]  N. Lois,et al.  Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. , 1998, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[8]  T. Chikama,et al.  Efficacy of substance P and insulin-like growth factor-1 peptides for preventing postsurgical superficial punctate keratopathy in diabetic patients , 2009, Japanese Journal of Ophthalmology.

[9]  A. Schmidt,et al.  The RAGE axis in early diabetic retinopathy. , 2005, Investigative ophthalmology & visual science.

[10]  S. Genuth,et al.  Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications , 2014, Clinical chemistry and laboratory medicine.

[11]  U. F. Ezepue.  Magnitude and causes of blindness and low vision in Anambra State of Nigeria (results of 1992 point prevalence survey). , 1997, Public health.

[12]  R. Cumming,et al.  Prevalence of cataract in Australia: the Blue Mountains eye study. , 1997, Ophthalmology.

[13]  Masaru Miyagi,et al.  Drusen proteome analysis: An approach to the etiology of age-related macular degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. , 1984, Archives of ophthalmology.

[15]  M. Araie,et al.  Advanced glycation end products in diabetic corneas. , 2000, Investigative ophthalmology & visual science.

[16]  A. Milam,et al.  Receptor for advanced glycation end products and age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.

[17]  B. Munoz,et al.  Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. , 2001, Diabetes care.

[18]  M. C. Leske,et al.  Prevalence of lens opacities in the Barbados Eye Study. , 1997, Archives of ophthalmology.

[19]  V. Monnier,et al.  Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. , 1981, Science.

[20]  S. Horiuchi,et al.  Advanced glycation end products in age-related macular degeneration. , 1998, Archives of ophthalmology.

[21]  G. Rubin,et al.  Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. , 2000, Archives of ophthalmology.

[22]  J. Glenn,et al.  The role of advanced glycation end products in retinal ageing and disease. , 2009, Biochimica et biophysica acta.

[23]  D. DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.

[24]  R. Klein,et al.  The relation of socioeconomic factors to age-related cataract, maculopathy, and impaired vision. The Beaver Dam Eye Study. , 1994, Ophthalmology.

[25]  T. Lyons,et al.  The Maillard reaction in vivo , 1991, Zeitschrift für Ernährungswissenschaft.

[26]  T. Chikama,et al.  Promotion of corneal epithelial wound healing in diabetic rats by the combination of a substance P-derived peptide (FGLM-NH2) and insulin-like growth factor-1 , 2003, Diabetologia.

[27]  Yuichi Kaji,et al.  The role of advanced glycation end products in retinal microvascular leukostasis. , 2003, Investigative ophthalmology & visual science.

[28]  Y. Tano,et al.  Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. , 1988, American journal of ophthalmology.